OPSUMIT/OPSYNVI(2) — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson OPSUMIT/OPSYNVI(2) — Sales to customers (Note 9) decreased by 0.9% to $1.16B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 0.9%, from $1.17B to $1.16B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and effective commercial execution for these specific therapies, while a decrease may signal increased competition or patent-related headwinds.
Detailed definition
This metric represents the total net revenue generated from the sale of specific pharmaceutical products within the pulm...
Peer comparison
Comparable to specialized therapeutic product revenue lines reported by other large-cap pharmaceutical companies in their segment disclosures.
jnj_segment_opsumit_opsynvi_sales_to_customers_note_9Historical Data
| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|
| Value | $1.05B | $1.10B | $1.17B | $1.04B | $1.17B | $1.16B |
| QoQ Change | — | +4.4% | +6.5% | -10.5% | +11.6% | -0.9% |
| YoY Change | — | — | — | -0.5% | +6.4% | -0.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's opsumit/opsynvi(2) — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported opsumit/opsynvi(2) — sales to customers (note 9) of $1.16B in Q3 2025.
- How has Johnson & Johnson's opsumit/opsynvi(2) — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's opsumit/opsynvi(2) — sales to customers (note 9) decreased by 0.9% year-over-year, from $1.17B to $1.16B.
- What does opsumit/opsynvi(2) — sales to customers (note 9) mean?
- The total revenue generated from the sales of specific pulmonary arterial hypertension medications.